3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several micro- devices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Royal Society of Chemistry (RSC)
2018
|
| Online Access: | http://hdl.handle.net/1721.1/118112 https://orcid.org/0000-0002-9199-9459 https://orcid.org/0000-0002-7232-304X |
| Summary: | Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several micro- devices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between tumor cells and non- tumor cell elements of the tumor microenvironment through direct cell – cell or cell – matrix contact or by the secretion of signaling factors such as cytokines, chemokines and growth factors. Given the challenges of personalized or precision cancer therapy, especially with the advent of novel immunotherapies, a critical need exists for more sophisticated ex vivo diagnostic systems that recapitulate patient-specific tumor biol- ogy with the potential to predict response to immune-based therapies in real-time. Here, we present de- tails of a method to screen for the response of patient tumors to immune checkpoint blockade therapy, first reported in Jenkins et al. Cancer Discovery, 2018, 8,196 – 215, with updated evaluation of murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS), including evaluation of the requirement for 3D microfluidic culture in MDOTS, demonstration of immune-checkpoint sensitivity of PDOTS, and ex- panded evaluation of tumor – immune interactions using RNA-sequencing to infer changes in the tumor – immune microenvironment. We also examine some potential improvements to current systems and dis- cuss the challenges in translating such diagnostic assays to the clinic. |
|---|